Search - tctmd.com

Displaying 41 - 60 of 157

Sort: Relevancy | Date

Presentation TCT Abstracts Posters 2018

Cost-Consequence Analysis of Cangrelor Use in High Angiographic Risk Percutaneous Coronary Intervention (PCI) Patients: A US Hospital Perspective

Presenter: Ivar S Jensen

September 25, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

Presentation JIM 2018

Cangrelor is ready for prime time

Presenter: Dominick J. Angiolillo

February 23, 2018

News Daily News

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

L.A. McKeown

December 20, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Why I Use Cangrelor for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Dmitriy N. Feldman

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

Shelley Wood

September 01, 2017

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

Todd Neale

August 29, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Daily News

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

Todd Neale

March 07, 2017

News Daily News

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

Michael O'Riordan

December 13, 2016

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

News Daily News

Sin ECA, el Análisis de Emparejamiento por Puntuación de la Propensión permite tomar una Decisión Informada entre Cangrelor y GPI en el Laboratorio de Cateterización

Yael L. Maxwell

December 06, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Debate: Making the Case for Very Limited Use of Cangrelor!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Sorin J. Brener

October 30, 2016

Advertisement

Cost-Consequence Analysis of Cangrelor Use in High Angiographic Risk Percutaneous Coronary Intervention (PCI) Patients: A US Hospital Perspective

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Cangrelor is ready for prime time

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Switching to and From Cangrelor: When and How?

Why I Use Cangrelor for Primary PCI in STEMI!

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

P2Y12 Inhibitor Pretreatment Questioned in STEMI

ESC Updates Guidelines for Treating STEMI Patients

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Sin ECA, el Análisis de Emparejamiento por Puntuación de la Propensión permite tomar una Decisión Informada entre Cangrelor y GPI en el Laboratorio de Cateterización

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Debate: Making the Case for Very Limited Use of Cangrelor!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content